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Amyloid-β reduces the expression of neuronal FAIM-L,
thereby shifting the inflammatory response mediated
by TNFα from neuronal protection to death
P Carriba*,1,2,3, S Jimenez3,4,5, V Navarro3,4,5, I Moreno-Gonzalez3,6,7, B Barneda-Zahonero1,2,3, RS Moubarak1,2,3, J Lopez-Soriano1,2,3,
A Gutierrez3,6, J Vitorica3,4,5 and JX Comella*,1,2,3
The brains of patients with Alzheimer’s disease (AD) present elevated levels of tumor necrosis factor-α (TNFα), a cytokine that has
a dual function in neuronal cells. On one hand, TNFα can activate neuronal apoptosis, and on the other hand, it can protect these
cells against amyloid-β (Aβ) toxicity. Given the dual behavior of this molecule, there is some controversy regarding its contribution
to the pathogenesis of AD. Here we examined the relevance of the long form of Fas apoptotic inhibitory molecule (FAIM) protein,
FAIM-L, in regulating the dual function of TNFα. We detected that FAIM-L was reduced in the hippocampi of patients with AD.
We also observed that the entorhinal and hippocampal cortex of a mouse model of AD (PS1M146LxAPP751sl) showed a reduction in
this protein before the onset of neurodegeneration. Notably, cultured neurons treated with the cortical soluble fractions of these
animals showed a decrease in endogenous FAIM-L, an effect that is mimicked by the treatment with Aβ-derived diffusible ligands
(ADDLs). The reduction in the expression of FAIM-L is associated with the progression of the neurodegeneration by changing the
inflammatory response mediated by TNFα in neurons. In this sense, we also demonstrate that the protection afforded by TNFα
against Aβ toxicity ceases when endogenous FAIM-L is reduced by short hairpin RNA (shRNA) or by treatment with ADDLs. All
together, these results support the notion that levels of FAIM-L contribute to determine the protective or deleterious effect of TNFα
in neuronal cells.
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Alzheimer’s disease (AD), the most common neurodegenera-
tive disease among the elderly, is characterized by synaptic
and memory defects, neuroinflammation, and progressive
neuronal death. As in other neurodegenerative diseases,
apoptosis is the main mechanism by which neurons die.1–3
This process has been reported to result from and be
reinforced by the neuroinflammatory environment.4,5
The brains of AD patients show high tumor necrosis
factor-α (TNFα) expression.6–9 Despite the elevated number of
reports implicating this cytokine in this disease, the role of TNF
signaling in AD is controversial. It has been reported that TNFα
protects neurons against amyloid-β (Aβ) toxicity both in vitro10
and in vivo,11 but it also contributes to exacerbating
neurodegeneration.12,13
TNFα plays a central role in inflammation and apoptosis.
TNF receptor 1 (TNFR1), the main receptor for TNFα,14 can
trigger two signaling pathways: survival or death. Survival
through the activation of the nuclear factor-κB (NFκB)
and/or FLIP-L (FLICE-like inhibitory protein, long isoform)-
dependent mitogen-activated protein kinase/extracellular-
signal-regulated kinase (MAPK/ERK) pathways15 or, under
certain circumstances, it can also trigger cell death by the
induction of the extrinsic apoptotic pathway.16 Indeed, TNFα
has the capacity to kill neurons only when the NFκB
transcription factor pathway is blocked17,18 or the macro-
molecular synthesis is inhibited.19,20 These observations
suggest that in neurons several regulatory proteins prevent
the induction of apoptosis at various stages of TNF signaling.21
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One such protein is the long form of Fas apoptotic inhibitory
molecule (FAIM) protein (FAIM-L).
The FAIM gene gives rise to two isoforms, the short (S) and
the long (L) form. FAIM-S iswidely expressed inmost cells and
tissues.22 However, in the nervous system FAIM-S does not
exert an anti-apoptotic function.23 FAIM-L is expressed
exclusively in neurons, where it serves as an antagonist of
death induced by TNFR1 and FAS.23
In this study, we found that FAIM-L expression is reduced in
hippocampal samples from AD patients and also in a
transgenic mouse model of the disease, PS1M146LxAPP751sl
(PS1xAPP). In primary cortical neurons, Aβ reduced the
expression of FAIM-L, thus suggesting that the expression of
this protein is associated with the progression of the disease.
We also show that the TNFα protection against Aβ toxicity is
suppressed when FAIM-L expression levels are low (by RNA
interference (RNAi) or by treatment with Aβ). Therefore, the
response of neurons to the same inflammatory stimulus
(TNFα) varies depending on the quantity of FAIM-L in the
neuron. Thus, we provide a molecular basis through which to
explain the protective or deleterious effect of TNFα in neuronal
cells during the progression of AD.
Results
FAIM-L is reduced in hippocampal samples from AD
patients and in the entorhinal and hippocampal cortex in
the transgenic PS1xAPP mouse. The pathogenesis of AD
involves multiple factors. In this regard, there are several lines
of evidence indicating that TNFα signaling makes a consider-
able contribution to this disease.24 Here we used quantitative
PCR (qPCR) to systematically analyze in postmortem
hippocampal samples from AD patients the proteins impli-
cated in this signaling pathway, including the antagonists of
DRs: CASP8 and FADD-like apoptosis regulator (CFLAR,
aliases cFLIP-L), Lifeguard, and FAIM-L (Supplementary
Information and Supplementary Figure S1).
Among the proteins analyzed, FAIM-L was most clearly
altered during the progression of BRAAK stages. BRAAK
staging describes the amount and distribution of neurofibrillary
tangles (NFT).25 This postmortem analysis is widely used
because it has been found to correlate well with the severity of
dementia.26–28 As FAIM-L is expressed only in neurons and
has been described as an antagonist of TNFα-induced
death,23 we focused on the role of this protein in AD.
A notable decrease in FAIM-L mRNA was observed with the
progression of the disease, being significant between control
individuals (BRAAK 0 and BRAAK II) and demented AD
patients (BRAAK V and BRAAK VI) (Figure 1a). Compared
with nondemented patients, FAIM-L mRNA at BRAAK V
decreased, although not reaching statistical significance. At
BRAAK stage VI, FAIM-L mRNA was reduced to 30% of
BRAAK 0 (individuals with no histopathological alteration of
the brain but younger) or BRAAK II (asymptomatic subjects
with similar age and with some histopathological modifica-
tions) (Figure 1a). Protein quantification of FAIM-L using the
neuronal marker NeuN for the normalization revealed similar
trend. Using NeuN allows discarding that the reduction of
FAIM-L was due to neuronal death. In BRAAK V, we observed
a diminution of FAIM-L levels but we were not able to detect
significant difference, as there was one out of range sample.
Nevertheless, at BRAAK stage VI, FAIM-L quantification
showed a reduction of 50% compared with normal cognition
individuals (BRAAK 0 or BRAAK II), confirming the results
obtained by mRNA analysis (Figures 1b and c).
The results in human samples prompted us to perform
similar analysis in the AD transgenic mouse model PS1xAPP.
These animals reproduce the temporal and regional neuro-
degeneration and neuroinflammation that occur in the brains
of AD patients. At 6 months of age, these animals show
degeneration in principal neurons and somatostatin/neuro-
peptide Y (SOM/NPY) interneurons in the entorhinal cortex.29
At this age, the analysis by qPCR in microdissected entorhinal
cortex showed a significant reduction of FAIM-L mRNA in the
transgenic animals compared with wild-type (WT) mice
(Figure 2A). In addition, the immunodetection of FAIM-L in
this cortical region displayed a marked reduction with age in
the transgenic animal (Figure 2B).
In the hippocampus, PS1xAPP mice develop pyramidal
neurodegeneration at ∼ 17–18 months of age.30–32 Western
blot quantification of the expression of FAIM-L in the
hippocampus of these animals revealed a noteworthy
decrease at 18 months (Figures 2C and D). Thus, in both
brain regions the decrease in FAIM-L expression occurs
before the increase in neuronal death.29,32
Aβ reduces the expression of FAIM-L. In order to analyze
the factors affecting the FAIM-L expression, we treated
primary mice cortical neurons with soluble fractions from
the cortex of PS1xAPP animals of different ages. By western
blot, we observed a dose-dependent reduction of FAIM-L, but
not FAIM-S, in neurons treated with the soluble fractions of
the transgenic animals but not those treated with the soluble
fractions of WT animals (Figure 3a). This reduction was
significant for the soluble fractions from both 6- and
18-month-old animals at a final protein concentration of
100 μg/ml in the culture media (Figure 3b). Thus, our data
further confirmed in vitro what we have already observed in
AD patients and in an AD animal model. We have previously
reported the presence of oligomeric Aβ (oAβ) in the soluble
fractions of these transgenic animals.32 According to this, in
cultured neurons these soluble fractions also induced death
(Figure 3c). Nonetheless, the death of neurons did not
explain the decrease in FAIM-L levels as FAIM-L protein
quantification was corrected with the neuron-specific marker
NeuN (Figures 3a and b).
The hippocampi of PS1xAPP mice show an increase in
soluble oAβ with age, specially the low-n oligomers.32 There-
fore we questioned whether oAβ causes the reduction in
FAIM-L expression. To address this point, we treated primary
neurons with increasing amounts of Aβ-derived diffusible
ligands (ADDLs) and examined FAIM-L expression bywestern
blot. The expression of FAIM-L, but not that of FAIM-S, in
cultured neurons decreased in a dose-dependent manner in
response to increasing concentrations of ADDLs (Figures 4a
and b). Moreover, the decrease in endogenous FAIM-L in
response to ADDL treatment also occurred in the neuron-like
cell model PC12 (Figure 4c). As in human samples and the
PS1xAPP mice, the downregulation of FAIM-L was also
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detected at the mRNA level in the cultured neurons
(Figure 4d), thus suggesting that Aβ is modulating the
expression of this protein rather than its degradation.
FAIM-L does not modify Aβ toxicity. FAIM-L is a potent
antagonist of death induced by the activation of the death
receptors (DRs) TNFR1 and FAS.23 DRs are cell surface
receptors that belong to the TNF superfamily and that trigger
apoptosis upon ligand binding. There are conflicting reports
regarding the mechanism by which Aβ kills neurons, with
some describing the activation of the extrinsic DR-mediated
apoptotic pathway.13,33–35 We found that 60% of the neuronal
death induced by Aβ is apoptotic as cotreatment with ADDLs
and the pancaspase inhibitor (Q-VD) led to a significant
reduction in neuronal death compared with that induced by
ADDLs alone (Figure 5a). Notice that the vehicle by itself
produced some death, and that death was not reverted with
Q-VD, indicating that the reduction in neuronal death in
the combined treatment (ADDL+Q-VD) is due only to the
prevention of apoptosis induced by ADDL. We next
addressed whether FAIM-L serves as a functional antagonist
of Aβ-induced neuronal death. For this purpose, we
modulated the endogenous levels of FAIM-L using recombi-
nant lentiviruses (Lv) for the overexpression (FAIM-L) or
downregulation by short hairpin RNAi (shFAIM-L) (Figure 5c).
In cultured neurons infected with these lentiviruses or the
corresponding scrambled or empty forms, the neuronal death
induced by Aβ toxicity did not show any relevant differences
when FAIM-L expression was modified (Figure 5b).
FAIM-L is required for the protective effect of TNFα
against Aβ-induced neuronal death. AD brains are cha-
racterized by the presence of neuroinflammatory mediators,
including increased TNFα during the progression of the
disease.6–9 The contribution of TNFα to AD pathogenesis is
highly controversial. It has been described that inflammation
Figure 1 Decrease in FAIM-L expression in hippocampal samples from AD patients. (a) mRNA levels of FAIM-L. Statistical analyses were done with Kruskal–Wallis test
followed by Dunn’s multiple comparison test. &&&Po0.0001 for comparisons between control nondemented (BRAAK 0 and BRAAK II) versus AD demented (BRAAK V and
BRAAK VI); and **Po0.001 between the different stages. (b) Representative western blot of FAIM-L, NeuN was used for normalization and tubulin for loading control.
(c) FAIM-L protein expression normalized with the neuronal marker NeuN, thereby discarding the possibility that the reduction was caused by neuronal loss. Mann–Whitney
nonparametric t-test. *P= 0.0382 BRAAK 0 versus BRAAK VI and &P= 0.0305 BRAAK II versus BRAAK VI. In both cases, data are mean±S.D. of three independent
experiments
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may be protective during onset of the disease,32 although the
persistence of inflammation may become detrimental.36 We
have previously described that TNFα activates pro-survival
intracellular signaling pathways through cFLIP-dependent
MAPK/ERK activation.15 Thus, in the context of Aβ toxicity,
we addressed whether TNFα has a protective or deleterious
effect and also how this effect is regulated by FAIM-L.
A relative high concentration of TNFα was used to reproduce
the elevated levels of this cytokine in pathological
conditions.37–39 Co-treatment of neurons with TNFα and Aβ
resulted in a significant prevention of cell death by 47%,
considering the death induced by the vehicle as basal death
(Figure 6a). More importantly, the protective effect of TNFα
was dependent on the endogenous levels of FAIM-L as
FAIM-L short hairpin RNA (shRNA) blocked the protective
effects of this cytokine (Figure 6a).
The cleavage of caspase-3 gives a good correlation with
neuronal death, as generally it is an indicator that the caspase
cascade is triggered. Caspase-3 was activated in the cultures
treated with ADDLs and abrogated in neurons co-treated with
Figure 2 Reduction of FAIM-L expression in transgenic PS1xAPP animals. (A) FAIM-L mRNA levels in laser-microdissected entorhinal cortex. *T-test with P= 0.039. Data
are mean± S.D. of three independent experiments. (B) Immunodetection of FAIM-L expression in the entorhinal cortex. In the entorhinal cortex, WT animals display a similar
immunostaining pattern for FAIM-L antibody at the ages analyzed (2 and 6 months old), without clear differences between superficial (I–III) and deep (IV–VI) layers. The PS1xAPP
transgenic animals, however, present a marked reduction in FAIM-L labeling, slightly at 2 months of age, but patent at 6 months. The decline in FAIM-L immunoreactivity does not
follow any apparent pattern, showing a reduction in all the layers, possibly less pronounced in neurons in layers II–III. Numbers at the bottom of the micrographs indicate the
relative integrated density of the FAIM-L labeling. Scale bar,100 μm. (C) Western blot of FAIM-L in samples from WTand transgenic animals at different ages. Three different
animals were used to obtain homogenates samples for each condition analyzed. (D) Protein FAIM-L quantification in hippocampus using β-actin as a loading control. Data are
mean± S.D. of three independent western blots with three animal samples for condition. T-test ***Po0.0001
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TNFα (Figure 6b).When FAIM-L was reduced by shRNA, once
again, we observed the appearance of the active caspase-3
fragment indicative of neuronal apoptosis (Figure 6b). All
these results support the notion that FAIM-L is required for
TNFα protection against ADDLs.
To ensure the specificity of the FAIM-L reduction for the
results obtained regarding TNFα protection, we generated a
lentivirus that expresses FAIM-L with a silent mutation
(smFAIM-L) that cannot be recognized by shFAIM-L, thus
impeding its downregulation when both lentiviruses are
co-infected (Figure 6c). The smFAIM-L greatly increased the
expression of FAIM-L (lane 3, Figure 6d), and this level was
maintained when shFAIM-L was expressed simultaneously
(lane 6, Figure 6d), in spite of shFAIM-L being highly efficient
in reducing endogenous FAIM-L (lane 5, Figure 6d). In these
conditions, that is, when the levels of FAIM-L were restored by
smFAIM-L, TNFα regained its capacity to prevent the effects of
Aβ toxicity in neurons (Figure 6e). On the basis of our findings,
we conclude that TNFα protects these cells against Aβ toxicity,
but that this protection occurs only when FAIM-L is present in
the neuron.
FAIM-L expression is not regulated by TNFα. TNFα
activates the transcription of protective genes by triggering
the transcription factor NFκB.40,41 Thus, we addressed
whether TNFα has the capacity to modulate FAIM-L expres-
sion. To this end, we treated primary cortical neurons with
increasing amounts of TNFα and analyzed the expression of
FAIM-L by western blot. TNFα alone did not modify the
endogenous levels of FAIM-L at any of the concentrations
tested. Neither in the simultaneous treatment with ADDLs
was TNFα able to modify the decrease in endogenous FAIM-L
induced by these ligands (Figures 7a and b). Accordingly, we
conclude that TNFα does not have the capacity to reverse the
downregulation of FAIM-L induced by Aβ treatment.
Reduction of FAIM-L by Aβ suppresses the protective
action of TNFα. The results obtained hitherto show that Aβ
decreases FAIM-L expression and also that this protein is
required to ensure TNFα protection against neuronal Aβ-
induced death. We further examined the capacity of TNFα to
protect neuronal cells against Aβ toxicity induced by several
amounts of Aβ. To this end, we treated cortical neurons with
increasing concentrations of ADDLs in the presence or
absence of TNFα and assessed neuronal death by counting
apoptotic nuclei (Figures 8a and b). Neuronal death induced
by ADDL followed a dose-dependent trend, with notable
death at 5 and 10 μM of Aβ. When neurons were also co-
treated with TNFα, this cytokine significantly prevented cell
death induced by 5 μM of ADDLs but not by 10 μM (Figures
8a and b). Western blot of caspase-3 cleavage showed a
similar result; the treatment with 5 and 10 μM of ADDLs
activated caspase-3, but co-treatment with TNFα prevented
this activation only in the presence of 5 μM of Aβ (Figure 8c).
We then sought to correlate these results with FAIM-L levels.
In these conditions, as we have previously shown, there was
a dose-dependent downregulation of FAIM-L expression
when neurons were treated with increasing concentrations
of Aβ. That is, FAIM-L expression decreased at 10 μM of Aβ,
but expression at 5 μM was similar to that observed in
vehicle-treated controls (Figure 8c). Thus, when neurons
were treated with a concentration of ADDLs that reduced
FAIM-L expression, TNFα was not able to exert a protective
effect. Next, we checked whether restoring FAIM-L levels
by exogenous overexpression would re-establish TNFα-
mediated protection. To carry out this experiment we used
a concentration of ADDL of 8 μM because this quantity of
ADDL ensured a detectable reduction in the levels of FAIM-L
without significantly compromising the neuronal viability.
The infection of neurons with a lentivirus that drives the
exogenous overexpression of FAIM-L gave rise to a
considerable increase in the levels of this protein, even when
endogenous FAIM-L was reduced by treatment with 8 μM of
Figure 3 Cortical soluble fractions from the PS1xAPP mice reduce FAIM-L levels
and also induce death in primary cortical neurons. (a) Primary cortical neurons were
treated for 48 h with different amounts of soluble fractions from WTor 6- or 18-month-
old transgenic mice. FAIM-L and FAIM-S were determined by western blot, using pan-
ERK and NeuN as a control of equal loading. (b) Quantification of three independent
western blots (**Po0.01 and *Po0.05, t-test). (c) Neurons were treated for 48 h with
the indicated amounts of the soluble fraction from WTand PS1xAPP mice of different
ages, and the neuronal death induced was determined by counting nuclei after
Hoechst staining. One-way ANOVA with multiple Newman–Keuls test gives
***Po0.001 between WT and 18 months with 100 μg/ml; and &&&Po0.001 and
&&Po0.01 in relation to untreated neurons
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ADDLs (Figure 8d). In these conditions, TNFα, partially but
significantly, prevented neuronal death, as assessed by
caspase-3 activation and apoptotic nuclei counts (Figures
8d and e). As expected, TNFα did not protect neurons
infected with the empty virus when they were treated with
8 μM of ADDLs because in this condition the amount of
FAIM-L was greatly reduced by Aβ (Figure 8e).
In conclusion, our results show that soluble Aβ down-
regulates the expression of FAIM-L in neurons and that this
reduction impedes the TNFα-mediated protection against
Aβ-induced neuronal death.
Discussion
Here we show that FAIM-L levels (protein and mRNA) are
reduced in patients with AD and also in the regions most
affected in this disease, namely the entorhinal cortex and the
hippocampus, in the transgenic mouse model of the disease
(PS1xAPP). Furthermore, when we added the soluble
fractions from these transgenic animals to cultured neurons,
FAIM-L expression also decreased. This effect was also
observed when we treated neuronal cells with ADDLs. These
observations thus reveal that Aβ downregulates FAIM-L
expression. We also demonstrate that the reduction in FAIM-
L, achieved by shRNA or by treating the cells with Aβ, impedes
TNFα protection against Aβ-induced cell death. All together,
these findings reveal a vicious circle in which, in addition to
toxicity, Aβ accumulation alters FAIM-L expression in neurons,
thus switching off the protective inflammatory response
induced by TNFα. On the basis of these results, we propose
a working model whereby normal levels of FAIM-L expression
in neurons allow TNFα-mediated protection against Aβ-
induced death, thus resulting in a beneficial inflammatory
response. However, when FAIM-L expression is reduced as a
result of accumulation of Aβ, then TNFα cannot protect from
Aβ, thus exposing neurons to death and contributing to
neurodegeneration. Hence, the response of neurons to the
same inflammatory stimulus (TNFα) differs in function of
the levels of FAIM-L present. FAIM-L determines whether the
TNFα response is beneficial or detrimental, therefore being
critical for neuronal fate.
FAIM was first described as an antagonist of FAS.42 The
FAIM gene comprises six exons, with two putative translation
initiation sites within exons II and III that generate two protein
isoforms.22 FAIM-S is widely expressed in many tissues,22
whereas FAIM-L is expressed exclusively in neurons.23
The mechanism by which FAIM-S expression is regulated in
B cells has recently been described.43 However, the regulation
of FAIM-L expression has not been resolved. We have
reported on the roles of the two isoforms in the nervous
system. The short form is required for neurite outgrowth
through the NFκB and MAPK/ERK pathways; however,
Figure 4 Amyloid-β reduces FAIM-L levels. (a) Primary cortical neurons were treated with the indicated amount of ADDLs and the corresponding vehicle control for 48 h and
then processed for FAIM-L and FAIM-S immunoblotting. Pan-ERK was used as a loading control. (b) Western blot quantification of three independent experiments (**Po0.01,
t-test). (c) PC12 cells were treated for 36 h with the indicated amount of ADDLs and the corresponding vehicle. FAIM-L immunoblot using pan-ERK and tubulin as a loading
control. No significant differences were observed with both loading controls. Numbers at the bottom of the lanes indicate the amount of FAIM-L in relation to tubulin. (d) The qPCR
for FAIM-L and FAIM-S after 48 h of the indicated treatments. ***Po0.001 between vehicle and 10 μMADDLs; and &&&Po0.001, &&Po0.01, and &Po0.05 for comparisons with
untreated neurons. One-way ANOVA with multiple Newman–Keuls test
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FAIM-S is unable to protect neurons from death induced by
trophic deprivation44 or DRs.23 Nonetheless, the neuronal
long form of the protein does exert protection against TNFR1-
and FAS-induced apoptosis.23 We recently described the
molecular mechanism by which FAIM-L protects against the
latter in neuronal cells.45 However, the mechanism by which
FAIM-L mediates TNFα protection against Aβ-induced cell
death is, at present, still unclear. In this study we show that Aβ
decreases FAIM-L expression without altering the expression
of FAIM-S. This observation suggests that the expression of
these two forms of the FAIM protein in neurons is subjected to
differential regulation. In addition, in neurons the quantity of
FAIM-L is higher than the FAIM-S, as evidenced in the qPCR in
Figure 4. The reduction in FAIM-L is not attributable to
neuronal death, as demonstrated by the neuronal loading
marker NeuN and also by the observation that at 100 μg/ml the
soluble fraction from 6-month-old transgenic mice caused a
significant reduction in FAIM-L expression whereas the death
induced was similar to that detected in age-matched WT
animals. The finding that FAIM-L mRNA levels are also
reduced indicates that Aβ modulates the expression of this
protein rather than its degradation.
The downregulation of FAIM-L has important consequences
for neuronal viability. This protein is a potent antagonist of
TNFα- and FAS-induced death in neuronal cells. The knock-
down of FAIM-L sensitizes neurons to death induced by these
DRs.23 In this regard, it has been suggested that the
expression of FAIM-L is reduced in dopaminergic neurons in
Parkinson’s disease, thus making this type of neurons more
vulnerable to FAS-induced death.46 However, in general,
neurons are resistant to death induced by DRs,47,48 although
DRs and ligands are expressed physiologically in the
brain.49–51 Indeed, TNFα-induced neuronal death requires
the blockage of NFκB17,18 or protein synthesis19,20 or the
depletion of FAIM-L expression.23 Consistent with this, as
shown in Figure 6, the knockdown of FAIM-L sensitized the
neurons to TNFα; and this effect was reverted when the cells
were co-infected with smFAIM-L to restore FAIM-L expression.
In the context of AD, the function of TNFα is controversial. It
protects neurons from Aβ toxicity10,11 but also contributes
to their neurodegeneration.12,13,33 Moreover its role in the
aggregation of NFT has been scarcely explored.52,53 In normal
conditions TNFα acts as a modulator of brain functions,54
participating in the control of synaptic transmission,55,56 and
Figure 5 FAIM-L does not modulate Aβ toxicity. (a) Primary cortical neurons were treated with 10 μM of ADDL or the equivalent in vehicle in the presence or not of 40 μM of
Q-VD for 48 h, and cell death was determined by counts of nuclear Hoechst staining. Data are mean± S.E.M. of three independent experiments. One-way ANOVA and Newman–
Keuls post hoc. ***Po0.001 for comparison between untreated and vehicle-treated cells; ###Po0.001 ADDLs versus ADDLs+Q-VD. (b) Cortical neurons were transduced for
6 days with lentivirus (Lv) for downregulation (shFAIM-L) or overexpression (FAIM-L) of FAIM-L with the corresponding scrambled (sc) or empty controls. Cells were then treated
with 5 μM ADDLs or the equivalent in vehicle for 48 h. Neuronal death was measured by counting nuclei stained with Hoechst. Data are mean± S.E.M. of three independent
experiments. (c) FAIM-L immunoblot after infection. Loading control determined by Naphthol blue
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Figure 6 FAIM-L is necessary for TNFα protection against Aβ-induced death. (a) Neurons were infected with shFAIM-L or the corresponding scrambled (sc) control for 6 days
and then treated for 48 h with 5 μM ADDLs and 100 ng/ml TNFα. Counts of nuclei after Hoechst staining were used to determine cell death. (b) Primary neurons treated as in
(a) were processed for western blot analysis of caspase-3 cleavage and FAIM-L expression. Pan-ERK was used as a loading control. (c) Scheme showing how the lentivirus-
expressing silent mutated FAIM-L (smFAIM-L) avoids shRNA downregulation, giving the expression of FAIM-L. (d) Expression of FAIM-L after 6 days of infection with the indicated
lentiviruses; *film least exposed shows that when both lentiviruses are expressed (shFAIM-L+smFAIM-L), the shFAIM-L downregulates endogenous FAIM-L. Loading control was
determined with pan-ERK. (e) Neurons were infected as indicated and treated for 48 h with 5 μM ADDLs and 100 ng/ml TNFα. Cell death was determined by counting nuclei after
Hoechst staining. In all cases, data are mean±S.E.M. of three independent experiment, except for (b) that is six. One-way ANOVA with Newman–Keuls test. ***Po0.001,
**Po0.01 and *Po0.05 for the same treatment; ##Po0.01 and #Po0.05 between ADDLs and ADDLs+TNFα
Figure 7 TNFα does not modulate the expression of FAIM-L. (a) Immunoblot of FAIM-L in neurons treated for 48 h with increasing concentrations of TNFα using pan-ERK as
a loading control. (b) Quantification of three independent western blots (***Po0.001, t-test)
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homeostatic plasticity also known as synaptic scaling.57–59
The distribution of the glial cells surrounding neuronal
synapses modulate these processes.60,61 The fine-tuning
control of the neurotransmission mediated by TNFα could
explain the deleterious effects on synaptic transmission when
deregulated. However, the neurodegeneration observed in AD
probably requires the downregulation of FAIM-L mediated by
Aβ. We assessed the neuronal viability with Hoechst counts
and cleavage of caspase-3. Despite that activation of this
caspase has been associated with other functions different to
apoptosis, in our model its cleavage appeared to be linked to
neuronal death as demonstrated with the pyknotic nuclei
observed with Hoechst staining, and the apparition of the
89 kDa fragment produced by the cleavage of poly (ADP-
ribose) polymerase (PARP) by caspase-3. The latter is a well-
defining and an ending event in the apoptotic process. Our
results demonstrate that the dual role on viability of TNFα
depends on the degree of FAIM-L expression. Although the
neuronal death induced by Aβ involves mainly the activation of
caspases, FAIM-L has no role on this effect. However, the
expression of this protein is required for the protection
conferred by TNFα. The overexpression of FAIM-L did not
enhance this protective effect, thereby indicating that FAIM-L
by itself was not responsible for the prevention of Aβ-induced
Figure 8 The reduction of FAIM-L by Aβ impedes TNFα protection. (a) Cortical neuronal death determined by counting nuclei stained with Hoechst after 48 h of the indicated
treatments. Data are mean±S.E.M. of three independent experiments. One-way ANOVA and Newman–Keuls post hoc. ***Po0.001, **Po0.01 and *Po0.05 (#versus
untreated; &versus its vehicle; and * for comparisons between ADDLs and ADDLs+TNFα). (b) Representative images of nuclear Hoechst staining. Scale bar, 50 μm.
(c) Immunoblot analysis of FAIM-L, PARP, and the cleavage fragment of caspase-3 in primary cortical neurons treated as in (a); pan-ERK was used as a control of loading.
(d) Neurons were infected for the overexpression of FAIM-L or an empty lentivirus for 6 days and then treated for 48 h with 8 μM ADDLs and 100 ng/ml TNFα. Western blot
analysis of caspase-3 cleavage and FAIM-L expression. Pan-ERK was used as a loading control. (e) Neurons were treated as in (d), and counts of nuclei after Hoechst staining
were used to determine cell death. Graph represents mean± S.E.M. **, ##Po0.01 (*versus same treatment and #between ADDLs and ADDLs+TNFα). One-way ANOVA
followed by multiple comparison Newman–Keuls test. In all cases, the experiments were repeated three times
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death when neurons were treated with TNFα. Interestingly,
FAIM-L does not appear to be a target gene of the TNF-
induced pro-survival pathway NFκB. Consequently, the treat-
ment of neuronswith TNFα did not reverse the downregulation
of FAIM-L caused by Aβ.
Overall, our results explain why neurodegeneration is
boosted by neuroinflammation when FAIM-L expression is
reduced in neurons. The transgenic mouse PS1xAPP, which
reproduces the human pathology and shows neuroinflamma-
tion and cortical neurodegeneration, also presents temporal
and regional age-dependent vulnerability, the entorhinal
cortex being the first area affected, followed by the hippo-
campus and subsequently an extensive part of the cortex. In
the transgenic animal, both regions, the entorhinal cortex and
the hippocampus, show a temporal correlation between
reduced FAIM-L expression and the consequent increase in
neuronal death.29,30,32 Thus, on the basis of the in vitro results,
we propose that the increase in soluble Aβ62,63 promotes the
reduction in neuronal FAIM-L expression and consequently
the loss of protection afforded by TNFα against Aβ toxicity,
hence increasing neuronal death. The same hypothesis could
be formulated for patients with AD. Although the progressive
reduction of FAIM-L mRNA with BRAAK stage severity may
mask neurodegeneration, the quantification of protein using
the neuronal marker NeuN also revealed a significant
decrease in FAIM-L expression between AD patients and
control nondemented subjects, thus indicating that the
reduction in FAIM-L is before neurodegeneration. Our
observations lead us to suggest that there is a threshold of
FAIM-L below which neurodegeneration is accelerated, as
documented in advanced BRAAK stages,25 going from mild
cognitive impairment (MCI) at BRAAK III–IV to AD at BRAAK
V–VI. Presumably, FAIM-L is not involved in the etiology of the
disease, but it can be determinant for the outcome. In this
regard, we propose that the degree of FAIM-L expression or its
evolution may be indicative of susceptibility to disease or
disease progression.
Materials and Methods
Reagents. To prepare ADDLs, the soluble oligomeric forms of Aβ (oAβ), we
followed previous protocols64,65 with some modifications. Cold lyophilized human
sequence Aβ 1–42 (Bachem, Weil am Rhein, Germany) was resuspended in ice-
cold HFIP (1,1,1,3,3,3-Hexafluor-2-propanol) (Sigma-Aldrich, Barcelona, Spain) to a
final concentration of 1 mM. The solution was incubated at room temperature (r.t.)
until it was transparent. Solvent was then allowed to evaporate overnight until a
peptide film formed. The films were stored at − 80ºC. The day before use, peptide
films were resuspended in DMSO (Sigma-Aldrich) to a final concentration of 5 mM,
and were further diluted to 100 μM with DMEM/F-12 Ham’s-phenol free (Life Tech,
Barcelona, Spain) and incubated at 4 °C for 24 h in order to achieve oligomer
formation. Before use, the solution was centrifuged for 10 min at 14 000 × g at 4ºC.
Supernatants containing the oligomers were diluted in the cell culture media to the
indicated final concentrations.
Lyophilized recombinant human TNFα (Biotrend, Köln, Germany) was diluted to
100 mg/ml in sterile DNase/RNase-free water. A final concentration of 100 ng/ml in
culture media was used.
The pan-caspase inhibitor Q-VD-OPh (MP Biomedicals, Santa Ana, CA, USA)
was diluted to 20 mM in sterile DNase/RNase-free water. A final concentration of
40 μM in culture media was used.
Human samples. The study was performed using samples from 22 cases
stored in the BTIN-Tissue Bank for Neurological Research, Madrid, and in the
Neurological Tissue Bank of IDIBELL-Hospital of Bellvitge, Barcelona. The cases
were scored for BRAAK stage for neurofibrillary tangles (0–VI). BRAAK 0 and
II correspond to individuals with normal cognition and BRAAK V and VI to AD
patients. There are scarcity of subjects of a similar age to AD patients without any
neurofibrillary tangles (BRAAK 0), and thus we also use BRAAK II (individuals with
normal cognition who present some histopathological alterations of the brain) for the
statistical comparisons. Table 1 provides details of the age, BRAAK stage, gender,
and delay postmortem before sample extraction.
Samples of hippocampi (60–80 μg) were homogenized in 1 ml of Tripure Isolation
Reagent (Roche, Sant Cugat del Vallès, Spain) as described previously for mouse
samples.29,31,32 After isolation of RNA samples, RNA integrity was assessed by
agarose gel electrophoresis. The yield of total RNAwas determined by measuring the
absorbance (260/280), and the recovery of RNA was comparable in all the groups
studied (0.3–0.4 μg/mg of tissue).
Retrotranscription (RT) was performed using random hexamers, 4 μg of total RNA
as template, and the High-Capacity cDNA Archive Kit (Applied Biosystems,
Barcelona, Spain), following the manufacturer’s recommendations.
PS1M146LxAPP751sl transgenic mouse samples. The generation of
PS1M146LxAPP751sl (PS1xAPP) mice has been reported previously.
66 Heterozygous
PS1xAPP double transgenic mice (C57BL/6 background) were generated by
crossing homozygous PS1 transgenic mice with heterozygous Thy1-APP751sl
ones. Only male mice were used in this study.
Laser capture microdissection of the entorhinal cortex was done as described
previously.29 Anesthetized animals (WT and PS1xAPP at 4 and 6 months of age;
n= 4/type/age) were killed by decapitation, and brains were quickly removed and
frozen. Brains were cut at 15 μm on a cryostat, and sections were collected on
Superfrost Plus slides (Fisher Scientific, Waltham, MA, USA) and stored at − 80ºC.
The entorhinal cortex from brain sections lightly stained with hematoxylin was
identified in stereotaxic coordinates following the mouse brain atlas.67 Laser capture
microdissection was performed using a Pix-Cell II instrument from Arcturus
Engineering (Mountain View, CA, USA). Cells were captured with a 30-μm laser
setting and CapSure LCM Caps (Arcturus). The laser was set to a pulse of 60 mV for
50 ms. After microdissection, the capture disk was cleared of nonspecific adhering
tissue using a CapSure Cleanup Pad (Arcturus). Entorhinal cortex RNAwas extracted
using the PicoPureTM RNA isolation kit. Capture disks with isolated material were
microcentrifuged and incubated in the extraction buffer for 30 min at 42ºC. Cell
extracts were then centrifuged and frozen at − 80ºC. For RNA isolation, cell extracts
were treated as indicated by the manufacturer (Arcturus). The integrity and amount of
purified RNA were analyzed using the RNA 6000 Pico Assay kit (Agilent
Technologies, Barcelona, Spain). Retrotranscription (RT) was done using the High-
Capacity cDNA Archive Kit (Applied Biosystems), following the manufacturer’s
recommendations. The RT-PCR was performed basically as previously described.29
Soluble fractions from mouse brains at the corresponding ages were obtained as
previously described.32 Briefly, brains were homogenated with a Teflon-glass
homogenizer in cold phosphate-buffered saline (PBS) with protease inhibitors
(Sigma-Aldrich) and ultracentrifuged at 120 000 × g at 4°C for 1 h. Immediately,
samples were aliquoted and store at − 80°C until use. Protein content was
determined by means of the Lowry assay.
Table 1 Human samples
Mean age±S.D. Sex Delay post-mortem mean h±S.D. BRAAK
47.83±5.81 4 Male and 2 female 7.2±3.9 0
72.66±9.43 4 Male and 2 female 6.2±4.5 II
85.75±4.42 1 Male and 3 female 11.2±4.0 V
77.16±13.24 2 Male and 4 female 11.0±5.8 VI
Aβ reduces FAIM-L changing the neuronal response to TNFα
P Carriba et al
10
Cell Death and Disease
Primary cortical culture. Cerebral cortices were dissected from WT fetal
C57BL/6 mouse embryos at day 16 (E16). Cortices without meninges were
trypsinized for 10 min at 37°C and mechanically dissociated through a Pasteur
pipette and filtered through a 40-μM nylon mesh in the presence of DNase I
(Roche). Cells were stained with Trypan blue, counted in a Neubauer chamber, and
then resuspended in Dulbecco’s modified Eagle’s medium (DMEM) with glutamine
supplemented with 5% heat-inactivated fetal bovine serum (FBS), 5% heat-
inactivated fetal horse serum (HS), 20 U/ml penicillin, and 20 μg/ml streptomycin.
Cells were plated in poly-L-Lysine (25 μg/ml) (Sigma-Aldrich)-coated plates at a
density of 1.6 × 105 cells/cm2. Purity of the cultures was determined by counts of
neurons labeled with NeuN with respect to the total number of cells labeled with
Hoechst, giving 97± 1.25% of neurons (n= 3). Infections were performed just after
seeding; in the case of infections with smFAIM-L, neurons were also reinfected
3 days before treatments. At 4 to 5 h after seeding, medium was replaced with
serum-free Neurobasal medium supplemented with 2% B27, 1% N2, 20 U/ml
penicillin, 20 μg/ml streptomycin, and 0.5 mM glutaMAX (Life Tech). Culture medium
was partially replaced every 3–4 days with fresh supplemented Neurobasal
medium. Cell cultures were kept at 37°C in a humidified incubator with 5% CO2 and
95% air. Neurons were processed after 8–9 days in vitro.
Cell culture. Rat pheochromocytoma PC12 cells were grown on plates coated
with Type I collagen (66.4 μg/ml; BD Biosciences) with DMEM supplemented with
6% heat-inactivated FBS and 6% heath-inactivated HS (Invitrogen), 10 mM HEPES,
20 U/ml penicillin, and 20 μg/ml streptomycin. Cells were kept at 37°C in a
humidified incubator with 5% CO2 and 95% air.
Quantitative PCR. For human samples, specific gene products were amplified
using the commercial hydrolysis TaqMan probes, following the instructions provided
by the manufacturer (Applied Biosystems) using either an ABI Prism 7000 or
7900HT sequence detector (Applied Biosystems). A first run of amplification with
three reference genes (18S, GAPDH, and actin) was done in order to determine
equal amounts of the three genes used as standard. To perform the relative
quantification using the comparative Ct delta method (Relative Quantification of
Gene Expression, bulletin 2, Applied Biosystems), three independent reactions for
each gene were done in parallel with the reference gene 18S.
The qPCR in primary neuronal cultures was done using cells that were scraped out
and washed once with ice-cold PBS. RNA was extracted following the protocol of the
RNeasy Mini Kit (Qiagen, Barcelona, Spain). Equal amounts of RNA were converted
to single-stranded cDNA using the High Capacity RNA-to-cDNA Kit (Applied
Biosystems). The qPCR was performed with Sybr Green PCR Master Mix (Applied
Biosystems) in an ABI Prism 7900 sequence detector (Applied Biosystems) with the
conditions indicated by the manufacturer. The sequences of the primers, designed
with span exon–exon junction, were as follows: faim-l (Mus musculus Fas apoptotic
inhibitory molecule, transcript variant 1) forward 5′-GCGCGGAGCAGACTGT-3′,
reverse 5′-TCCAGGCTATAGAGAGGGCTT-3′; faim-s (Mus musculus Fas apoptotic
inhibitory molecule, transcript variant 2) forward 5′-GCGGAGCAGCCCTCTCTA-3′,
reverse 5′-CCTGATGTGGTCCCATGTTCA-3′; l27 forward 5′-AGCTGTCATCGTGA
AGAA-3′, reverse 5′- CTTGGCGATCTTCTTCTTGCC-3′; and GAPDH forward
5′-TGTGAACGGATTTGGCCGTA-3′, reverse 5′-ACTGTGCCGTTGAATTTGCC-3′.
The results of the qPCR were normalized by l27. Similar results were obtained with
GAPDH as the reference gene.
Lentiviral particles. The lentiviral particles used to modify FAIM-L quantity in
neurons were: short-hairpin RNA (shFAIM-L) to knock down, FAIM-L to
overexpress, and the silent mutated (smFAIM-L) to overexpress FAIM-L when the
endogenous FAIM-L was downregulated by the shFAIM-L; with their corresponding
scrambled (sc) form or empty vector controls.23 Lentiviral particles were produced
as previously described.23
Cell viability assays. Cell death was analyzed by nuclear Hoechst staining. At
4 h before the end of treatments, cells were stained by adding Hoechst 33258 to a
final concentration of 0.3 μg/ml in the media. After this time, pictures were taken in a
NIKON Eclipse TE2000-s (Nikon, Tokyo, Japan). Condensed or fragmented nuclei
were counted as dead cells.68 For each condition, 800 to 1000 cells were counted in
fields of 100–200 neurons/field. All the counts were repeated at least three times in
independent cultures.
Western blot. Neurons were harvested and washed once with ice-cold PBS,
then lysed in triton lysis buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl,
10 mM EDTA, and 1% Triton with a cocktail of protease (Roche) and phosphatase
(Sigma-Aldrich) inhibitors for 30 min at 4ºC. Supernatants were obtained after
centrifugation at 14 000 × g for 10 min at 4ºC. Protein concentration was quantified
by a modified Lowry assay (DC protein assay; Bio-Rad, Hercules, CA, USA). Next,
7–20 μg of protein was resolved by SDS-polyacrylamide gels and transferred onto
PVDF (Millipore Ibérica, Madrid, Spain). Membranes were incubated with blocking
solution (5% non-fat dry milk in TBS with 0.1% tween-20 (TBS-T)) for 1 h at r.t.
Primary antibodies prepared in blocking solution were incubated overnight at 4ºC.
After washes with TBS-T, membranes were probed with the appropriate specific
peroxidase-conjugated secondary antibody and developed using the EZ-ECL
chemiluminescence detection kit (Biological Industries, Kibbutz Beit Haemek,
Israel). The primary antibodies used were anti-FAIM-L (antibody generated with the
specific sequence presented in FAIM-L) and anti-FAIM-S (both in-house, tested and
validated for both WB and immunohisto/cytochemistry23); anti-caspase-3, anti-PARP
(Cell Signalling Technologies, Beverly, MA, USA); anti-NeuN, anti-panERK
(Millipore); and anti-tubulin (Sigma-Aldrich).
Animal ethics committees. All experiments involving the PS1xAPP mice
were carried out in accordance with the European Union regulations (Council
Directive 86/609/ECC of 24 November 1986) and approved by the Committee of
Animal Use for Research at Malaga University, Spain (RD 1201/2005 of 10 October
2005). Regarding the primary cultures, the procedures followed the experimental
protocol approved by the Vall d’Hebron Institutional Review Board (CEIC).
Statistical analysis. All the experiments were performed at least three times.
The statistics used are indicated in the figure legends with the significance obtained.
For the analysis of human samples, we used nonparametric tests: the equivalent to
ANOVA test Kruskal–Wallis followed by Dunn’s multiple comparison test; and the
nonparametric t-test Mann–Whitney. For the statistical analysis of the in vitro
experiments, we used parametric tests: one-way ANOVA with multiple Newman–
Keuls test to analyze the differences between groups and t-test to compare two sets
of data.
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